Impact of Defibrotide in the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation.

Rémi TilmontIbrahim Yakoub-AghaNassima RamdaneMicha SrourValérie CoiteuxLéonardo MagroPascal OdouNicolas SimonDavid Beauvais

Published in: The Annals of pharmacotherapy (2022)

Defibrotide does not seem to have a protective effect on aGVHD in patients undergoing allo-HCT. Based on what has been reported to date and on these results, defibrotide should not be considered for the prevention of aGVHD outside clinical trials.

Keyphrases

patients undergoing
clinical trial
stem cell transplantation
liver failure
bone marrow
respiratory failure
drug induced
hepatitis b virus
aortic dissection
intensive care unit
cell proliferation
extracorporeal membrane oxygenation
study protocol